pDNA Vaccines for Neurodegenerative Diseases and Cancer

The inventive concept applies the core technology of synthetic pDNA vaccines against COVID-19 to develop novel treatments for neurodegenerative diseases and cancer, leveraging the same plasmid design and production expertise to induce protective immune responses against disease-related proteins and tumor antigens.

The original patent disclosed synthetic pDNA vaccines against COVID-19, but the technology's potential applications extend beyond infectious diseases. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, and cancer are significant unmet medical needs, with limited effective treatments available. The new inventive concept addresses these limitations by adapting the pDNA vaccine technology to target disease-related proteins and tumor antigens, providing a promising solution for these debilitating conditions.

The inventive concept involves designing and producing pDNA vaccines that encode proteins binding to neurodegenerative disease-related proteins or tumor antigens. These pDNA vaccines are engineered to induce a protective immune response against the targeted proteins, reducing disease progression and promoting recovery. The pDNA vaccines can be administered via various routes, including intramuscular or intradermal injection, and may be combined with adjuvants to enhance immunogenicity. The technology's flexibility allows for the development of personalized therapies, tailoring the pDNA vaccine to individual patients' needs.

The new inventive concept's novelty lies in its application of the original pDNA vaccine technology to entirely new disease areas, leveraging the same plasmid design and production expertise to address unmet medical needs in neurodegenerative diseases and cancer. The inventive step involves the recognition of the potential for pDNA vaccines to target disease-related proteins and tumor antigens, and the adaptation of the technology to achieve this goal.

Alternative embodiments of the inventive concept may involve the use of different plasmid designs, such as self-amplifying RNA or mRNA-based vaccines, or the incorporation of additional components, like adjuvants or immunomodulators, to enhance the immune response. Variations of the technology could also target other diseases, such as autoimmune disorders or infectious diseases beyond COVID-19.

The inventive concept has significant commercial potential in the pharmaceutical industry, with potential applications in neurodegenerative diseases, cancer, and beyond. The global market for neurodegenerative disease treatments is projected to reach $45 billion by 2025, while the cancer vaccine market is expected to reach $12 billion by 2027. The technology's adaptability and flexibility make it an attractive solution for pharmaceutical companies and investors seeking to address unmet medical needs.